University of Texas 'Picosatellite' to be launched from space shuttle to begin milestone mission

AUSTIN, TexasIn an initial step toward the first successful rendezvous and docking of very small satellites without human control, a pair of miniature "picosatellites" built by University of Texas at Austin and Texas A&M University engineering students will be launched into orbit this month from S...

Bedford Laboratories(TM) to Begin Shipping Fluconazole Injection in PVC Flexible Containers

BEDFORD, Ohio, April 13 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the addition of Fluconazole injection 2 mg / mL in PVC flexible containers to its existing Fluconazole injection line. This product is AP rated and is equivalent to Diflucan(R) ...

MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury Geron Corporation (Nasdaq: GERN ) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patient...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

DUBLIN, Calif., Nov. 20 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that it has received clearance to initiate clinical trials with SGI-1776, an inhibitor of Pim kinases. ...

Diamyd Gets Authorization to Begin Phase III Study in the US

STOCKHOLM, March 14 /PRNewswire-FirstCall/ -- Diamyd Medical AB ( http://www.omxgroup.com, ticker: DIAM B; http://www.otcqx.com, ticker DMYDY). The FDA has given Diamyd Medical permission to start a Phase III clinical study in type 1 diabetes patients in the US with the therapeutic diabetes...

Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA

ANN ARBOR, Mich., Jan. 28 /PRNewswire/ -- Velcura Therapeutics Inc., an early stage biotechnology company developing therapies for bone disease, recently completed a successful Investigational New Drug application (IND) to the U.S. Food and Drug Administration (FDA). The IND enables Velcura to...

ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer

LEUVEN, Belgium and LUND, Sweden, January 18 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International AB (Nordic Exchange: BINV) announce today that they have received approval from the regulatory authorities in Denmark to initiate ...

National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment

Genzyme Genetics to Provide Testing for Important Cancer and Leukemia Group B Study WESTBOROUGH, Mass., Dec. 4 /PRNewswire-FirstCall/ -- Genzyme Genetics, a business unit of Genzyme Corporation (Nasdaq: GENZ ), announced today its participation in a Cancer and Leu...

China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility

SHANGHAI, China, Nov. 30 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has re...

ExonHit Therapeutics: Allergan and ExonHit's First Collaboration Compound to Begin Human Clinical Trials

PARIS, August 28 /PRNewswire-FirstCall/ -- ExonHit Therapeutics, a drug and diagnostic discovery company, today announced that its drug discovery collaboration with Allergan Inc. (NYSE: AGN ), a global speciality pharmaceutical and medical device company, has reached a success milestone. As a...

First Seed Sales of Dedicated Energy Crops Begin

THOUSAND OAKS, Calif., Dec. 11 /PRNewswire/ -- Ceres, Inc. announced today that it has begun booking switchgrass and high-biomass sorghum seed under its Blade Energy Crops label. The highly anticipated launch marks the first seed sales of non-food, low-carbon crops developed specifically as raw ma...

National $100m pilot program to begin mapping cancer genome

The Cancer Genome Atlas is intented to be for cancers what the Human Genome Project was for people a map that will let scientists better distinguish different types of cancer. That means they could prescribe treatments that are more likely to work on patients with particular cancers, rather tha...

Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast

... 29th Annual Global Growth Conference on Thursday, August 13. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11:30 a.m., Eastern Daylight Time (8:30 a.m., Pacific Daylight Time). The presentation will be available through the conference website at ...

NeurogesX Reports Second Quarter 2009 Results

...val of Qutenza and conducting pre-commercialization activities related to pricing, reimbursement, and detailed market research. We expect that we will begin to invest more heavily, although keeping our conservative focus, in preparatory activities for a potential commercial launch of Qutenza in the United ...

Microbix Sales Grow 22% For Nine Months

...hnology under commercial conditions. Microbix expects to see more companies begin to work with the technology over the next few months." The Company recent...cturing facility. The Hunan group have proposed to self-finance Phase I and begin construction by the second quarter of 2010. The advantage of this plan is t...

The Law Offices of Brian D. Witzer Wins 6+ Million Dollar Verdict

...e serious life-threatening disorders which affect the skin and mucous membranes, which can also result in blindness, organ failure and death. Symptoms begin with flu-like symptoms followed by a painful red or purplish rash that spreads and blisters, eventually causing the skin and mucosal membranes to shed...

PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009

... 2009. PharmAthene management will be hosting a conference call to discuss its second quarter 2009 financial results. The call is scheduled to begin at 11:00 a.m. Eastern Time on Thursday, August 13, 2009, and is expected to last approximately 45 minutes. The dial-in number within the United...

Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305

...ated to the licensed Hsp90 technology, including CUDC-305. Curis currently expects that Debiopharm will file an application with health authorities to begin Phase I clinical testing for CUDC-305 in Fall 2009. Curis will receive an up-front license fee and, pending approval of such application, Curis will r...

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...oval for Amigal according to Subpart H regulations. Amicus has begun submitting the Phase 3 protocol to investigational sites worldwide and expects to begin the dosing of subjects in the second half of this year. As previously announced, the Phase 3 trial will evaluate the efficacy, safety, and phar...

GeoVax Labs, Inc. Provides Clinical Studies Update

... of the projected participants. On the therapeutic front, we are in the midst of planning the details of a Phase 1 human clinical trial and expect to begin this trial, assuming FDA approval, in the first quarter of 2010." Preventative Clinical Trials - Phase 2a The preventative trial, designate...

Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures

...esents a revolutionary technology in wound closure made possible by bidirectional fixation within the wound. Its patented design allows the surgeon to begin closure at the midpoint of the wound and suture in two directions from the midpoint. Barbs within the Quill SRS product distribute tension across the ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

...g developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis i...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...sociated with the reduction in force and facilities move; (vi) the ability to achieve EVR, RVR and SVR in the Phase II study; (vii) the expectation to begin patient dosing in the ANA598 Phase II study within the next several weeks; and (viii) plans to explore partnership opportunities as a potential path t...

Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System

... center for the PHOENIX application. The company expects to meet with CBER during the next 60 days to identify any additional information required to begin the feasibility trial. About Cardiogenesis Corporation Cardiogenesis is a medical device company specializing in the therapies for the treatm...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

... code 1742471. To access a live webcast of the call, please log on to Mylan's Web site ( www.mylan.com ) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on www.mylan.com for approximately seven day...

Osteotech Resumes Shipments of Bulgarian Tissue

...tissue and found no instances of contamination. As a result of this favorable outcome, Osteotech lifted its self-imposed temporary suspension and will begin distributing tissue grafts processed from OCBG donors to its foreign distributors immediately. "The results of the afssaps inspections and test...

Neurocrine Biosciences Reports Second Quarter 2009 Results

...sity of Otago, Christchurch School of Medicine and Health Sciences, New Zealand, in collaboration with Neurocrine, has obtained regulatory approval to begin a pilot study in patients with Acute Decompensated Heart Failure. These patients are the target population for the Urocortin 2 mechanism of action and...

United States FDA Clears the REGEN Trial to Test Bioheart's Combination Gene and Stem Cell Therapy in Heart Failure Patients

...lood vessel formation in damaged hearts. "We are happy to be able to begin the REGEN trial to test this promising product candidate in heart failure p...l therapy for cardiovascular disease." The U.S. trial is expected to begin this year. After completing the REGEN safety protocol with one-month follow...

Cynosure Reports Second Quarter 2009 Financial Results

... "Although the third quarter traditionally has been the weakest for the aesthetic industry, we are hopeful that the macroeconomic environment will begin to stabilize as we move through the balance of 2009," Davin said. "We continue to carefully manage our business, with the goal to be cash flow neutra...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

... of oral mucositis. In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to radiation treatment and then throughout the subsequent six weeks of planned therapy. The first 140 patients being trea...

QRxPharma Initiates Comparative Phase 2 Proof-of-Concept Study for MoxDuo(TM) IV Pain Therapy

...ell as reduced nausea and vomiting may permit accelerated patient recovery while providing superior pain relief. This will enable physical therapy to begin sooner, saving time and money for both patient and payer." QRxPharma expects the study to be completed before the end of 2009. Forw...

Vistaar and the Professional Pricing Society Partner to Present Premier Symposium for Pricing Practitioners

...nt of PPS. These presentations will focus on delivering compelling and practical strategies to overcome the pricing challenges companies face as they begin to reemerge from the economic downturn. The event is intended for innovative companies with complex pricing environments across a broad range of indu...

A drug-dispensing contact lens

...pplications in conditions such as glaucoma and dry-eye which require frequent daily eye drops. They have begun to test the lens in animals and plan to begin human testing as soon as possible. The technology recently won the Life Sciences track in MIT's 100K Entrepreneurship Competition. ...

Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing

...t line, human cardiomyocytes. Under the licensed technology, pluripotent stem cells are engineered to include a selectable "marker." As the stem cells begin to differentiate into different terminal cell types (e.g. heart, blood, neural cells, etc.), the marker allows researchers to identify and select a pa...

China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results

...nce growth in both of our businesses from the prior year. In addition, we continued to focus on the completion of our new facility, which we expect to begin making a meaningful contribution to revenue in the third quarter of fiscal 2010." Gross profit for the quarter increased 21.0% to $10.6 million...

University of Florida Shands Cancer Center Selects OnCore(r) to Support its Collaborative Research Goals

...this, the cancer center clinical trials office will roll-out the system first. Once that group has fully rolled-out the system, the cancer center will begin reaching out to other research departments doing oncology trials throughout the university. "We hope that OnCore will help us to expand the c...

EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator

...uman clinical trials." Based on the success of these experiments, EnVivo has now entered preclinical development with EVP-0962 and expects to begin clinical trials in 2010. About EnVivo Pharmaceuticals EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical compa...

Brain Monitor Eliminates Need for Routine Oxygen With Propofol - Friedberg's Triad Unveiled

... to their stomach. Brain-monitored, propofol-based anesthesia is the ideal. "Once patients understand what is in their best interest and they begin to ask for brain monitored PK anesthesia, greater safety will result," says Friedberg. Disclaimer: Dr. Friedberg has no financial involvement...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

...g developed for the treatment of GI GVHD, a common and potentially life-threatening complication of hematopoietic cell transplantation. DOR expects to begin a confirmatory Phase 3 clinical trial of orBec(R) for the treatment of acute GI GVHD and a Phase 1/2 clinical trial of DOR201 in radiation enteritis i...

2009: Immunotec announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process

... Immunotec Receives NHPD/Health Canada Authorization to begin a Study on the Effect of the Cysteine-Rich Whey Protein Isolate (Immunocal(R)) in Combination with Physical Exercise on Muscle Function, Body ...